Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT00734994

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy

Sponsor: Mark Dewhirst

Conditions Superficial Bladder Cancer Transitional Cell Carcinoma of Bladder

Interventions Hyperthermia System Mitomycin C

Updated 6 times since 2017 Last updated: Jun 1, 2015 Started: Apr 30, 2008 Primary completion: Feb 28, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Superficial Bladder Cancer and Transitional Cell Carcinoma of Bladder and is currently completed. Mark Dewhirst leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mark Dewhirst

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States